Life in 3D is never flat: 3D models to optimise drug delivery

Journal of Controlled Release

Volumn 215, Issue , 2015, Pages 39-54

  Fitzgerald, Kathleen A ^a   Malhotra, Meenakshi ^a   Curtin, Caroline M ^b,c   O'Brien, Fergal J ^b,c   O'Driscoll, Caitriona M ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^c TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

3D cell culture; Biomaterials; Drug delivery; In vitro biopharmaceutical tool; The 3 Rs

Indexed keywords

ANIMAL CELL CULTURE; BIOASSAY; BIOCHIPS; BIOMATERIALS; CELL CULTURE; CELLS; CYTOLOGY; DRUG DELIVERY; DRUG PRODUCTS; LIFE CYCLE; MICROARRAYS; PRODUCT DEVELOPMENT; SCAFFOLDS (BIOLOGY); TOXICITY;

3-D CELL CULTURE; CELL CULTURE MODELS; DIFFERENT STAGES; FORMULATION DEVELOPMENT; IN-VITRO; MICROENVIRONMENTS; MULTICELLULAR SPHEROID; THE 3 RS;

THREE DIMENSIONAL COMPUTER GRAPHICS;

MOLECULAR SCAFFOLD; NEW DRUG;

BIOCHIP; CELL CULTURE; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG METABOLISM; HEART; HUMAN; HYDROGEL; IN VITRO STUDY; INTERMETHOD COMPARISON; INTESTINE; KIDNEY; LIVER; MICROFLUIDICS; MULTICELLULAR SPHEROID; NONHUMAN; PRIORITY JOURNAL; PRODUCT DEVELOPMENT; REVIEW; TOXICITY TESTING; TUMOR MICROENVIRONMENT; ANIMAL; BIOLOGICAL MODEL; NEOPLASM; PATHOLOGY; THREE DIMENSIONAL IMAGING; TISSUE CULTURE TECHNIQUE;

ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; IMAGING, THREE-DIMENSIONAL; MODELS, BIOLOGICAL; NEOPLASMS; SPHEROIDS, CELLULAR; TISSUE CULTURE TECHNIQUES;

EID: 84939825735     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2015.07.020     Document Type: Review

References (138)

1. S. Morgan, P. Grootendorst, J. Lexchin, C. Cunningham, and D. Greyson The cost of drug development: a systematic review Health Policy 100 2011 4 17 (Amsterdam, Netherlands)
2. T. Hartung Three Rs potential in the development and quality control of pharmaceuticals Altex 18 Suppl. 1 2001 3 13
3. M. Hay, D.W. Thomas, J.L. Craighead, C. Economides, and J. Rosenthal Clinical development success rates for investigational drugs Nat. Biotechnol. 32 2014 40 51
4. T.M. Desrochers, E. Palma, and D.L. Kaplan Tissue-engineered kidney disease models Adv. Drug Deliv. Rev. 69-70C 2014 67 80
5. W. Bains Failure Rates in Drug Discovery and Development-Will We Ever Get Any Better? DDW Drug Discov. World 5 2004 9 19
6. Z.P. Qureshi, E. Seoane-Vazquez, R. Rodriguez-Monguio, K.B. Stevenson, and S.L. Szeinbach Market withdrawal of new molecular entities approved in the United States from 1980 to 2009 Pharmacoepidemiol. Drug Saf. 20 2011 772 777
7. E. Novik, T.J. Maguire, P. Chao, K.C. Cheng, and M.L. Yarmush A microfluidic hepatic coculture platform for cell-based drug metabolism studies Biochem. Pharmacol. 79 2010 1036 1044
8. I. Cavero Optimizing the preclinical/clinical interface: an Informa Life Sciences conference 12-13 December, 2006, London, UK Expert Opin. Drug Saf. 6 2007 217 224
9. D.W. Hutmacher Biomaterials offer cancer research the third dimension Nat. Mater. 9 2010 90 93
10. N.T. Elliott, and F. Yuan A review of three-dimensional in vitro tissue models for drug discovery and transport studies J. Pharm. Sci. 100 2011 59 74
11. M. Darnell, T. Schreiter, K. Zeilinger, T. Urbaniak, T. Soderdahl, I. Rossberg, B. Dillner, A.L. Berg, J.C. Gerlach, and T.B. Andersson Cytochrome P450-Dependent Metabolism in HepaRG Cells Cultured in a Dynamic Three-Dimensional Bioreactor Drug Metab. Dispos. 39 2011 1131 1138
12. F. Pampaloni, E.G. Reynaud, and E.H.K. Stelzer The third dimension bridges the gap between cell culture and live tissue Nat. Rev. Mol. Cell Biol. 8 2007 839 845
13. K. Chitcholtan, E. Asselin, S. Parent, P.H. Sykes, and J.J. Evans Differences in growth properties of endometrial cancer in three dimensional (3D) culture and 2D cell monolayer Exp. Cell Res. 319 2013 75 87
14. A.J. Engler, F. Rehfeldt, S. Sen, and D.E. Discher Microtissue elasticity: Measurements by atomic force microscopy and its influence on cell differentiation Methods Cell Biol. 83 2007 (521-+)
15. A.J. Engler, C. Carag-Krieger, C.P. Johnson, M. Raab, H.Y. Tang, D.W. Speicher, J.W. Sanger, J.M. Sanger, and D.E. Discher Embryonic cardiomyocytes beat best on a matrix with heart-like elasticity: scar-like rigidity inhibits beating J. Cell Sci. 121 2008 3794 3802
16. A.J. Engler, S. Sen, H.L. Sweeney, and D.E. Discher Matrix elasticity directs stem cell lineage specification Cell 126 2006 677 689
17. A. Abbott Cell culture: biology's new dimension Nature 424 2003 870 872
18. J.T. Erler, and V.M. Weaver Three-dimensional context regulation of metastasis Clin. Exp. Metastasis 26 2009 35 49
19. E. Cukierman, R. Pankov, D.R. Stevens, and K.M. Yamada Taking cell-matrix adhesions to the third dimension Science 294 2001 1708 1712
20. M.W. Tibbitt, and K.S. Anseth Hydrogels as Extracellular Matrix Mimics for 3D Cell Culture Biotechnol. Bioeng. 103 2009 655 663
21. T. Hoshiba, and M. Tanaka Optimization of the tissue source, malignancy, and initial substrate of tumor cell-derived matrices to increase cancer cell chemoresistance against 5-fluorouracil Biochemical and biophysical research communications 2015
22. H.K. Dhiman, A.R. Ray, and A.K. Panda Three-dimensional chitosan scaffold-based MCF-7 cell culture for the determination of the cytotoxicity of tamoxifen Biomaterials 26 2005 979 986
23. J.L. Stevens, and T.K. Baker The future of drug safety testing: expanding the view and narrowing the focus Drug Discov. Today 14 2009 162 167
24. D. Huh, B.D. Matthews, A. Mammoto, M. Montoya-Zavala, H.Y. Hsin, and D.E. Ingber Reconstituting Organ-Level Lung Functions on a Chip Science 328 2010 1662 1668
25. V. Baumans Use of animals in experimental research: an ethical dilemma? Gene Ther. 11 Suppl. 1 2004 S64 S66
26. H. Olson, G. Betton, D. Robinson, K. Thomas, A. Monro, G. Kolaja, P. Lilly, J. Sanders, G. Sipes, W. Bracken, M. Dorato, K. Van Deun, P. Smith, B. Berger, and A. Heller Concordance of the toxicity of pharmaceuticals in humans and in animals Regul. Toxicol. Pharmacol. 32 2000 56 67
27. W.M.S. Russell, R.L. Burch, and C.W. Hume The principles of humane experimental technique 1959
28. L.G. Griffith, and M.A. Swartz Capturing complex 3D tissue physiology in vitro, Nature reviews Mol. Cell. Biol. 7 2006 211 224
29. D.W. Hutmacher, R.E. Horch, D. Loessner, S. Rizzi, S. Sieh, J.C. Reichert, J.A. Clements, J.P. Beier, A. Arkudas, O. Bleiziffer, and U. Kneser Translating tissue engineering technology platforms into cancer research J. Cell. Mol. Med. 13 2009 1417 1427
30. D. Herrmann, J.R. Conway, C. Vennin, A. Magenau, W.E. Hughes, J.P. Morton, and P. Timpson Three-dimensional cancer models mimic cell-matrix interactions in the tumour microenvironment Carcinogenesis 35 8 2014 1671 1679
31. S. Even-Ram, and K.M. Yamada Cell migration in 3D matrix Curr. Opin. Cell Biol. 17 2005 524 532
32. K.M. Yamada, and E. Cukierman Modeling tissue morphogenesis and cancer in 3D Cell 130 2007 601 610
33. D.W. Hutmacher Scaffolds in tissue engineering bone and cartilage Biomaterials 21 2000 2529 2543
34. E.G. Tierney, K. McSorley, C.L. Hastings, S.A. Cryan, T. O'Brien, M.J. Murphy, F.P. Barry, F.J. O'Brien, and G.P. Duffy High levels of ephrinB2 over-expression increases the osteogenic differentiation of human mesenchymal stem cells and promotes enhanced cell mediated mineralisation in a polyethyleneimine-ephrinB2 gene-activated matrix J. Control. Release 165 2013 173 182
35. E.G. Tierney, G.P. Duffy, A.J. Hibbitts, S.A. Cryan, and F.J. O'Brien The development of non-viral gene-activated matrices for bone regeneration using polyethyleneimine (PEI) and collagen-based scaffolds J. Control. Release 158 2012 304 311
36. C.M. Murphy, A. Matsiko, M.G. Haugh, J.P. Gleeson, and F.J. O'Brien Mesenchymal stem cell fate is regulated by the composition and mechanical properties of collagen-glycosaminoglycan scaffolds J. Mech. Behav. Biomed. 11 2012 53 62
37. M.B. Keogh, F.J. O'Brien, and J.S. Daly Substrate stiffness and contractile behaviour modulate the functional maturation of osteoblasts on a collagen-GAG scaffold Acta Biomater. 6 2010 4305 4313
38. M. Ravi, V. Paramesh, S.R. Kaviya, E. Anuradha, and F.D. Paul Solomon 3D cell culture systems: Advantages and applications J. Cell. Physiol. 230 2015 16 26
39. E.S. Place, J.H. George, C.K. Williams, and M.M. Stevens Synthetic polymer scaffolds for tissue engineering Chem. Soc. Rev. 38 2009 1139 1151
40. J. Zhu, and R.E. Marchant Design properties of hydrogel tissue-engineering scaffolds Expert Rev. Med. Devices 8 2011 607 626
41. Y. Peck, and D.A. Wang Three-dimensionally engineered biomimetic tissue models for in vitro drug evaluation: delivery, efficacy and toxicity Expert Opin. Drug Deliv. 10 2013 369 383
42. J.L. Drury, and D.J. Mooney Hydrogels for tissue engineering: scaffold design variables and applications Biomaterials 24 2003 4337 4351
43. T.W. Gilbert, T.L. Sellaro, and S.F. Badylak Decellularization of tissues and organs Biomaterials 27 2006 3675 3683
44. A.L. Brown, E.M. Srokowski, X.Z. Shu, G.D. Prestwich, and K.A. Woodhouse Development of a model bladder extracellular matrix combining disulfide cross-linked hyaluronan with decellularized bladder tissue Macromol. Biosci. 6 2006 648 657
45. L.W. Dunne, Z. Huang, W. Meng, X. Fan, N. Zhang, Q. Zhang, and Z. An Human decellularized adipose tissue scaffold as a model for breast cancer cell growth and drug treatments Biomaterials 35 2014 4940 4949
46. L.E. Fitzpatrick, and T.C. McDevitt Cell-derived matrices for tissue engineering and regenerative medicine applications Biomater. Sci. 3 2015 12 24
47. M.L. Decaris, A. Mojadedi, A. Bhat, and J.K. Leach Transferable cell-secreted extracellular matrices enhance osteogenic differentiation Acta Biomater. 8 2012 744 752
48. M.L. Kutys, A.D. Doyle, and K.M. Yamada Regulation of cell adhesion and migration by cell-derived matrices Exp. Cell Res. 319 2013 2434 2439
49. H. Lu, T. Hoshiba, N. Kawazoe, I. Koda, M. Song, and G. Chen Cultured cell-derived extracellular matrix scaffolds for tissue engineering Biomaterials 32 2011 9658 9666
50. R. Bjerkvig Spheroid Culture in Cancer Research 1991 Taylor & Francis
51. G. Hamilton Multicellular spheroids as an in vitro tumor model Cancer Lett. 131 1998 29 34
52. L.A. Kunz-Schughart, J.P. Freyer, F. Hofstaedter, and R. Ebner The use of 3-D cultures for high-throughput screening: The multicellular spheroid model J. Biomol. Screen. 9 2004 273 285
53. S.Y. Proskuryakov, and V.L. Gabai Mechanisms of tumor cell necrosis Curr. Pharm. Des. 16 2010 56 68
54. W. Mueller-Klieser Tumor biology and experimental therapeutics Crit. Rev. Oncol. Hematol. 36 2000 123 139
55. R. Daw, and J. Finkelstein Lab on a chip Nature 442 2006 (367-367)
56. M. Tehranirokh, A.Z. Kouzani, P.S. Francis, and J.R. Kanwar Microfluidic devices for cell cultivation and proliferation Biomicrofluidics 7 2013 51502
57. J. El-Ali, P.K. Sorger, and K.F. Jensen Cells on chips Nature 442 2006 403 411
58. R. Siegel, J. Ma, Z. Zou, and A. Jemal Cancer statistics, 2014 CA Cancer J. Clin. 64 2014 9 29
59. S. Talukdar, and S.C. Kundu A Non-Mulberry Silk Fibroin Protein Based 3D In Vitro Tumor Model for Evaluation of Anticancer Drug Activity Adv. Funct. Mater. 22 2012 4778 4788
60. A. Frankel, R. Buckman, and R.S. Kerbel Abrogation of taxol-induced G2-M arrest and apoptosis in human ovarian cancer cells grown as multicellular tumor spheroids Cancer Res. 57 1997 2388 2393
61. J.I. Johnson, S. Decker, D. Zaharevitz, L.V. Rubinstein, J.M. Venditti, S. Schepartz, S. Kalyandrug, M. Christian, S. Arbuck, M. Hollingshead, and E.A. Sausville Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials Br. J. Cancer 84 2001 1424 1431
62. J.M. Lee, P. Mhawech-Fauceglia, N. Lee, L.C. Parsanian, Y.G. Lin, S.A. Gayther, and K. Lawrenson A three-dimensional microenvironment alters protein expression and chemosensitivity of epithelial ovarian cancer cells in vitro Lab. Investig. 93 2013 528 542
63. Z. Xu, Y. Gao, Y. Hao, E. Li, Y. Wang, J. Zhang, W. Wang, Z. Gao, and Q. Wang Application of a microfluidic chip-based 3D co-culture to test drug sensitivity for individualized treatment of lung cancer Biomaterials 34 2013 4109 4117
64. S.V. Sharma, D.A. Haber, and J. Settleman Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents Nat. Rev. Cancer 10 2010 241 253
65. C.S. Shin, B. Kwak, B. Han, and K. Park Development of an in vitro 3D tumor model to study therapeutic efficiency of an anticancer drug Mol. Pharm. 10 2013 2167 2175
66. M.A. dit Faute, L. Laurent, D. Ploton, M.F. Poupon, J.C. Jardillier, and H. Bobichon Distinctive alterations of invasiveness, drug resistance and cell-cell organization in 3D-cultures of MCF-7, a human breast cancer cell line, and its multidrug resistant variant Clin. Exp. Metastasis 19 2002 161 168
67. H. Sha, Z. Zou, K. Xin, X. Bian, X. Cai, W. Lu, J. Chen, G. Chen, L. Huang, A.M. Blair, P. Cao, and B. Liu Tumor-penetrating peptide fused EGFR single-domain antibody enhances cancer drug penetration into 3D multicellular spheroids and facilitates effective gastric cancer therapy J. Control. Release 200 2015 188 200
68. Y.-J. Kim, H.-I. Bae, O.K. Kwon, and M.-S. Choi Three-dimensional gastric cancer cell culture using nanofiber scaffold for chemosensitivity test Int. J. Biol. Macromol. 45 2009 65 71
69. L. David, V. Dulong, D. Le Cerf, L. Cazin, M. Lamacz, and J.P. Vannier Hyaluronan hydrogel: an appropriate three-dimensional model for evaluation of anticancer drug sensitivity Acta Biomater. 4 2008 256 263
70. D. Loessner, K.S. Stok, M.P. Lutolf, D.W. Hutmacher, J.A. Clements, and S.C. Rizzi Bioengineered 3D platform to explore cell-ECM interactions and drug resistance of epithelial ovarian cancer cells Biomaterials 31 2010 8494 8506
71. Z. Yang, and X. Zhao A 3D model of ovarian cancer cell lines on peptide nanofiber scaffold to explore the cell-scaffold interaction and chemotherapeutic resistance of anticancer drugs Int. J. Nanomedicine 6 2011 303 310
72. I. Rizvi, J.P. Celli, C.L. Evans, A.O. Abu-Yousif, A. Muzikansky, B.W. Pogue, D. Finkelstein, and T. Hasan Synergistic enhancement of carboplatin efficacy with photodynamic therapy in a three-dimensional model for micrometastatic ovarian cancer Cancer Res. 70 2010 9319 9328
73. K.A. Fitzgerald, J. Guo, E.G. Tierney, C.M. Curtin, M. Malhotra, R. Darcy, F.J. O'Brien, and C.M. O'Driscoll The use of collagen-based scaffolds to simulate prostate cancer bone metastases with potential for evaluating delivery of nanoparticulate gene therapeutics Biomaterials 66 2015 53 66
74. X. Xu, C.R. Sabanayagam, D.A. Harrington, M.C. Farach-Carson, and X. Jia A hydrogel-based tumor model for the evaluation of nanoparticle-based cancer therapeutics Biomaterials 35 2014 3319 3330
75. L.A. Gurski, A.K. Jha, C. Zhang, X. Jia, and M.C. Farach-Carson Hyaluronic acid-based hydrogels as 3D matrices for in vitro evaluation of chemotherapeutic drugs using poorly adherent prostate cancer cells Biomaterials 30 2009 6076 6085
76. I. Serebriiskii, R. Castelló-Cros, A. Lamb, E.A. Golemis, and E. Cukierman Fibroblast-derived 3D matrix differentially regulates the growth and drug-responsiveness of human cancer cells Matrix Biol. 27 2008 573 585
77. A.L. Howes, G.G. Chiang, E.S. Lang, C.B. Ho, G. Powis, K. Vuori, and R.T. Abraham The phosphatidylinositol 3-kinase inhibitor, PX-866, is a potent inhibitor of cancer cell motility and growth in three-dimensional cultures Mol. Cancer Ther. 6 2007 2505 2514
78. C. Fischbach, R. Chen, T. Matsumoto, T. Schmelzle, J.S. Brugge, P.J. Polverini, and D.J. Mooney Engineering tumors with 3D scaffolds Nat. Methods 4 2007 855 860
79. A. Birgersdotter, R. Sandberg, and I. Ernberg Gene expression perturbation in vitro - a growing case for three-dimensional (3D) culture systems Semin. Cancer Biol. 15 2005 405 412
80. S.J. Fey, and K. Wrzesinski Determination of Drug Toxicity Using 3D Spheroids Constructed From an Immortal Human Hepatocyte Cell Line Toxicol. Sci. 127 2012 403 411
81. Y.A. Luqmani Mechanisms of Drug Resistance in Cancer Chemotherapy Med. Princ. Pract. 14 Suppl. 1 2005 35 48
82. B. Prabhakarpandian, M.C. Shen, J.B. Nichols, C.J. Garson, I.R. Mills, M.M. Matar, J.G. Fewell, and K. Pant Synthetic tumor networks for screening drug delivery systems J. Control. Release 201 2015 49 55
83. L. Gibot, L. Wasungu, J. Teissie, and M.P. Rols Antitumor drug delivery in multicellular spheroids by electropermeabilization J. Control. Release 167 2013 138 147
84. W.L. Diehl-Jones, and D.F. Askin The neonatal liver, Part 1: embryology, anatomy, and physiology Neonatal Netw. 21 2002 5 12
85. R. Baudoin, L. Griscom, J.M. Prot, C. Legallais, and E. Leclerc Behavior of HepG2/C3A cell cultures in a microfluidic bioreactor Biochem. Eng. J. 53 2011 172 181
86. G. Tuschl, B. Lauer, and S.O. Mueller Primary hepatocytes as a model to analyze species-specific toxicity and drug metabolism Expert Opin. Drug Metab. Toxicol. 4 2008 855 870
87. P. Godoy, N.J. Hewitt, U. Albrecht, M.E. Andersen, N. Ansari, S. Bhattacharya, J.G. Bode, J. Bolleyn, C. Borner, J. Bottger, A. Braeuning, R.A. Budinsky, B. Burkhardt, N.R. Cameron, G. Camussi, C.S. Cho, Y.J. Choi, J.C. Rowlands, U. Dahmen, G. Damm, O. Dirsch, M.T. Donato, J. Dong, S. Dooley, D. Drasdo, R. Eakins, K.S. Ferreira, V. Fonsato, J. Fraczek, R. Gebhardt, A. Gibson, M. Glanemann, C.E.P. Goldring, M.J. Gomez-Lechon, G.M.M. Groothuis, L. Gustavsson, C. Guyot, D. Hallifax, S. Hammad, A. Hayward, D. Haussinger, C. Hellerbrand, P. Hewitt, S. Hoehme, H.G. Holzhutter, J.B. Houston, J. Hrach, K. Ito, H. Jaeschke, V. Keitel, J.M. Kelm, B.K. Park, C. Kordes, G.A. Kullak-Ublick, E.L. LeCluyse, P. Lu, J. Luebke-Wheeler, A. Lutz, D.J. Maltman, M. Matz-Soja, P. McMullen, I. Merfort, S. Messner, C. Meyer, J. Mwinyi, D.J. Naisbitt, A.K. Nussler, P. Olinga, F. Pampaloni, J.B. Pi, L. Pluta, S.A. Przyborski, A. Ramachandran, V. Rogiers, C. Rowe, C. Schelcher, K. Schmich, M. Schwarz, B. Singh, E.H.K. Stelzer, B. Stieger, R. Stober, Y. Sugiyama, C. Tetta, W.E. Thasler, T. Vanhaecke, M. Vinken, T.S. Weiss, A. Widera, C.G. Woods, J.J. Xu, K.M. Yarborough, and J.G. Hengstler Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME Arch. Toxicol. 87 2013 1315 1530
88. C. Abadie-Viollon, H. Martin, N. Blanchard, D. Pekthong, P. Bachellier, G. Mantion, B. Heyd, F. Schuler, P. Coassolo, E. Alexandre, and L. Richert Follow-up to the pre-validation of a harmonised protocol for assessment of CYP induction responses in freshly isolated and cryopreserved human hepatocytes with respect to culture format, treatment, positive reference inducers and incubation conditions Toxicol. in Vitro 24 2010 346 356
89. N.J. Hewitt, M.J. Lechon, J.B. Houston, D. Hallifax, H.S. Brown, P. Maurel, J.G. Kenna, L. Gustavsson, C. Lohmann, C. Skonberg, A. Guillouzo, G. Tuschl, A.P. Li, E. LeCluyse, G.M. Groothuis, and J.G. Hengstler Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies Drug Metab. Rev. 39 2007 159 234
90. A. Madan, R.A. Graham, K.M. Carroll, D.R. Mudra, L.A. Burton, L.A. Krueger, A.D. Downey, M. Czerwinski, J. Forster, M.D. Ribadeneira, L.S. Gan, E.L. LeCluyse, K. Zech, P. Robertson Jr., P. Koch, L. Antonian, G. Wagner, L. Yu, and A. Parkinson Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes Drug Metab. Dispos. 31 2003 421 431
91. P. Gunness, D. Mueller, V. Shevchenko, E. Heinzle, M. Ingelman-Sundberg, and F. Noor 3D Organotypic Cultures of Human HepaRG Cells: A Tool for In Vitro Toxicity Studies Toxicol. Sci. 133 2013 67 78
92. A. Legendre, S. Jacques, F. Dumont, J. Cotton, P. Paullier, M.J. Fleury, and E. Leclerc Investigation of the hepatotoxicity of flutamide: pro-survival/apoptotic and necrotic switch in primary rat hepatocytes characterized by metabolic and transcriptomic profiles in microfluidic liver biochips Toxicol. in Vitro 28 2014 1075 1087
93. J.M. Prot, A.-S. Briffaut, F. Letourneur, P. Chafey, F. Merlier, Y. Grandvalet, C. Legallais, and E. Leclerc Integrated proteomic and transcriptomic investigation of the acetaminophen toxicity in liver microfluidic biochip PLoS ONE 6 2011 e21268
94. P. Chao, T. Maguire, E. Novik, K.C. Cheng, and M.L. Yarmush Evaluation of a microfluidic based cell culture platform with primary human hepatocytes for the prediction of hepatic clearance in human Biochem. Pharmacol. 78 2009 625 632
95. R.P. Myers, B. Li, A. Fong, A.A. Shaheen, and H. Quan Hospitalizations for acetaminophen overdose: a Canadian population-based study from 1995 to 2004 BMC Public Health 7 2007 143
96. R. Baudoin, A. Legendre, S. Jacques, J. Cotton, F. Bois, and E. Leclerc Evaluation of a liver microfluidic biochip to predict in vivo clearances of seven drugs in rats J. Pharm. Sci. 103 2014 706 718
97. S.B. Leite, I. Wilk-Zasadna, J.M. Zaldivar, E. Airola, M.A. Reis-Fernandes, M. Mennecozzi, C. Guguen-Guillouzo, C. Chesne, C. Guillou, P.M. Alves, and S. Coecke Three-dimensional HepaRG model as an attractive tool for toxicity testing Toxicol. Sci. 130 2012 106 116
98. A.I. Astashkina, B.K. Mann, G.D. Prestwich, and D.W. Grainger A 3-D organoid kidney culture model engineered for high-throughput nephrotoxicity assays Biomaterials 33 2012 4700 4711
99. D. Choudhury, and Z. Ahmed Drug-associated renal dysfunction and injury, Nature clinical practice Nephrology 2 2006 80 91
100. T.C. Fuchs, and P. Hewitt Biomarkers for drug-induced renal damage and nephrotoxicity - an overview for applied toxicology AAPS J. 13 2011 615 631
101. A.I. Astashkina, B.K. Mann, G.D. Prestwich, and D.W. Grainger Comparing predictive drug nephrotoxicity biomarkers in kidney 3-D primary organoid culture and immortalized cell lines Biomaterials 33 2012 4712 4721
102. B. Subramanian, D. Rudym, C. Cannizzaro, R. Perrone, J. Zhou, and D.L. Kaplan Tissue-engineered three-dimensional in vitro models for normal and diseased kidney Tissue Eng. A 16 2010 2821 2831
103. T.M. DesRochers, L. Suter, A. Roth, and D.L. Kaplan Bioengineered 3D human kidney tissue, a platform for the determination of nephrotoxicity PLoS ONE 8 2013 e59219
104. N. Shimony, R. Gorodetsky, G. Marx, D. Gal, R. Rivkin, A. Ben-Ari, A. Landsman, and Y.S. Haviv Fibrin microbeads (FMB) as a 3D platform for kidney gene and cell therapy Kidney Int. 69 2006 625 633
105. L. Choucha-Snouber, C. Aninat, L. Grsicom, G. Madalinski, C. Brochot, P.E. Poleni, F. Razan, C.G. Guillouzo, C. Legallais, A. Corlu, and E. Leclerc Investigation of ifosfamide nephrotoxicity induced in a liver-kidney co-culture biochip Biotechnol. Bioeng. 110 2013 597 608
106. K.J. Jang, A.P. Mehr, G.A. Hamilton, L.A. McPartlin, S. Chung, K.Y. Suh, and D.E. Ingber Human kidney proximal tubule-on-a-chip for drug transport and nephrotoxicity assessment Integr. Biol. 5 2013 1119 1129
107. C.S. Hughes, L.M. Postovit, and G.A. Lajoie Matrigel: a complex protein mixture required for optimal growth of cell culture Proteomics 10 2010 1886 1890
108. D. Huh, G.A. Hamilton, and D.E. Ingber From 3D cell culture to organs-on-chips Trends Cell Biol. 21 2011 745 754
109. S. Schaaf, A. Shibamiya, M. Mewe, A. Eder, A. Stohr, M.N. Hirt, T. Rau, W.H. Zimmermann, L. Conradi, T. Eschenhagen, and A. Hansen Human Engineered Heart Tissue as a Versatile Tool in Basic Research and Preclinical Toxicology PLoS ONE 6 2011
110. B. Fermini, and A.A. Fossa The impact of drug-induced QT interval prolongation on drug discovery and development, Nature reviews Drug Discov. 2 2003 439 447
111. J.K. Gwathmey, K. Tsaioun, and R.J. Hajjar Cardionomics: a new integrative approach for screening cardiotoxicity of drug candidates 2009
112. M. Nasr, N. Nafee, H. Saad, and A. Kazem Improved antitumor activity and reduced cardiotoxicity of epirubicin using hepatocyte-targeted nanoparticles combined with tocotrienols against hepatocellular carcinoma in mice Eur. J. Pharm. Biopharm. 88 2014 216 225
113. J.C. Ralphe, and W.J. de Lange 3D engineered cardiac tissue models of human heart disease: learning more from our mice Trends Cardiovasc. Med. 23 2013 27 32
114. K. Baar, R. Birla, M.O. Boluyt, G.H. Borschel, E.M. Arruda, and R.G. Dennis Self-organization of rat cardiac cells into contractile 3-D cardiac tissue FASEB J. 19 2005 275 277
115. U. Muhlhauser, O. Zolk, T. Rau, F. Munzel, T. Wieland, and T. Eschenhagen Atorvastatin desensitizes beta-adrenergic signaling in cardiac myocytes via reduced isoprenylation of G-protein gamma-subunits FASEB J. 20 2006 785 787
116. A. El-Armouche, J. Singh, H. Naito, K. Wittkopper, M. Didie, A. Laatsch, W.H. Zimmermann, and T. Eschenhagen Adenovirus-delivered short hairpin RNA targeting PKCalpha improves contractile function in reconstituted heart tissue J. Mol. Cell. Cardiol. 43 2007 371 376
117. W.J. de Lange, L.F. Hegge, A.C. Grimes, C.W. Tong, T.M. Brost, R.L. Moss, and J.C. Ralphe Neonatal mouse-derived engineered cardiac tissue: a novel model system for studying genetic heart disease Circ. Res. 109 2011 8 19
118. M. Hambleton, H. Hahn, S.T. Pleger, M.C. Kuhn, R. Klevitsky, A.N. Carr, T.F. Kimball, T.E. Hewett, G.W. Dorn, and W.J. Koch Pharmacological-and gene therapy-based inhibition of protein kinase Cα/β enhances cardiac contractility and attenuates heart failure Circulation 114 2006 574 582
119. G. Vunjak Novakovic, T. Eschenhagen, and C. Mummery Myocardial Tissue Engineering: In Vitro Models Cold Spring Harb. Perspect. Biol. Med. 4 2014
120. Z. Ma, S. Koo, M.A. Finnegan, P. Loskill, N. Huebsch, N.C. Marks, B.R. Conklin, C.P. Grigoropoulos, and K.E. Healy Three-dimensional filamentous human diseased cardiac tissue model Biomaterials 35 2014 1367 1377
121. G.J. Mahler, M.B. Esch, R.P. Glahn, and M.L. Shuler Characterization of a Gastrointestinal Tract Microscale Cell Culture Analog Used to Predict Drug Toxicity Biotechnol. Bioeng. 104 2009 193 205
122. K.S. Pang Modeling of intestinal drug absorption: roles of transporters and metabolic enzymes (for the Gillette Review Series) Drug Metab. Dispos. 31 2003 1507 1519
123. M.B. Esch, J.H. Sung, J. Yang, C. Yu, J. Yu, J.C. March, and M.L. Shuler On chip porous polymer membranes for integration of gastrointestinal tract epithelium with microfluidic 'body-on-a-chip' devices Biomed. Microdevices 14 2012 895 906
124. Y. Imura, Y. Asano, K. Sato, and E. Yoshimura A Microfluidic System to Evaluate Intestinal Absorption Anal. Sci. 25 2009 1403 1407
125. H.J. Kim, and D.E. Ingber Gut-on-a-Chip microenvironment induces human intestinal cells to undergo villus differentiation Integr. Biol. 5 2013 1130 1140
126. M.J. O'Neill, L. Bourre, S. Melgar, and C.M. O'Driscoll Intestinal delivery of non-viral gene therapeutics: physiological barriers and preclinical models Drug Discov. Today 16 2011 203 218
127. S.H. Kim, M. Chi, B. Yi, S.H. Kim, S. Oh, Y. Kim, S. Park, and J.H. Sung Three-dimensional intestinal villi epithelium enhances protection of human intestinal cells from bacterial infection by inducing mucin expression Integr. Biol. 6 2014 1122 1131
128. R.B. van Breemen, and Y. Li Caco-2 cell permeability assays to measure drug absorption Expert Opin. Drug Metab. Toxicol. 1 2005 175 185
129. M.A. Alam, F.I. Al-Jenoobi, and A.M. Al-mohizea Everted gut sac model as a tool in pharmaceutical research: limitations and applications J. Pharm. Pharmacol. 64 2012 326 336
130. L.L. Clarke A guide to Ussing chamber studies of mouse intestine Am. J. Physiol. Gastrointest. Liver Physiol. 296 2009 G1151 G1166
131. N. Li, D. Wang, Z. Sui, X. Qi, L. Ji, X. Wang, and L. Yang Development of an improved three-dimensional in vitro intestinal mucosa model for drug absorption evaluation Tissue Eng. Part C Methods 19 2013 708 719
132. F. Leonard, E.M. Collnot, and C.M. Lehr A three-dimensional coculture of enterocytes, monocytes and dendritic cells to model inflamed intestinal mucosa in vitro Mol. Pharm. 7 2010 2103 2119
133. J. Yu, S. Peng, D. Luo, and J.C. March In vitro 3D human small intestinal villous model for drug permeability determination Biotechnol. Bioeng. 109 2012 2173 2178
134. T. Ohnuma, H. Arkin, and J.F. Holland Effects of cell density on drug-induced cell kill kinetics in vitro (inoculum effect) Br. J. Cancer 54 1986 415 421
135. F.M. Watt Effect of seeding density on stability of the differentiated phenotype of pig articular chondrocytes in culture J. Cell Sci. 89 Pt 3 1988 373 378
136. C.E. Holy, M.S. Shoichet, and J.E. Davies Engineering three-dimensional bone tissue in vitro using biodegradable scaffolds: Investigating initial cell-seeding density and culture period J. Biomed. Mater. Res. 51 2000 376 382
137. M. Dvir-Ginzberg, I. Gamlieli-Bonshtein, R. Agbaria, and S. Cohen Liver tissue engineering within alginate scaffolds: Effects of cell-seeding density on hepatocyte viability, morphology, and function Tissue Eng. 9 2003 757 766
138. D.G. Wallace, and J. Rosenblatt Collagen gel systems for sustained delivery and tissue engineering Adv. Drug Deliv. Rev. 55 2003 1631 1649